Propylthiouracil Induced p-ANCA+ Pyoderma Gangrenosum with Inflammatory Bowel Disease in Pregnancy

Authors

  • Larasati Budiyarto Dermatology and Venereology Department, Fatmawati Central General Hospital, Jakarta
  • Devi Arofah Mumtazah Department of Dermatology and Venereology, Fatmawati Central General Hospital
  • Sara Ester Triatmoko Department of Plastic Reconstructive and Aesthetic Surgery, Fatmawati Central General Hospital

Keywords:

inflammatory bowel disease, pregnancy, propylthiouracil, pyoderma gangrenosum, split-thickness skin graft surgery

Abstract

Introduction: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful ulcers with undermined edges and peripheral erythema. Global incidence of PG is estimated to be 3 to 10 cases per million people per year, affecting individuals aged between 25 to 54 years. Case Report: This case reports a 34-year-old female with deep painful ulcerous non-healing wounds on both legs which first appear on her pregnancy. Prolonged consumption of propylthiouracil (PTU) as treatment of hyperthyroidism was found. Gastrointestinal symptoms were denied. Histopathological examination revealed intense neutrophilic infiltration of dermis in skin biopsy and chronic ulcerative inflammation in ileum and colon biopsy. Result of p-ANCA was positive. Patient was diagnosed with pyoderma gangrenosum associated with drug-induced due to PTU use and inflammatory bowel disease. Combination therapy of systemic corticosteroid, two split-thickness skin graft (STSG) surgeries, oral dapsone, appropriate wound care, and management to eliminate predisposing factors resulted in favorable outcome. Conclusion : Pyoderma gangrenosum has been considered a challenging disease to diagnose and treat. It is important for clinicians to enhance knowledge of diagnosis and management of PG in order to yield a better prognosis. Keywords : inflammatory bowel disease, pregnancy, propylthiouracil, pyoderma gangrenosum, split-thickness skin graft surgery

References

Maverakis E, Marzano A v., Le ST, Callen JP, Brüggen MC, Guenova E, et al. Pyoderma gangrenosum. Vol. 6, Nature Reviews Disease Primers. Nature Research; 2020.

Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, et al. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. Int Wound J. 2018 Dec 1;15(6):875–9.

Clayman E, Marcet K, Kuykendall L, Atisha D. Pyoderma Gangrenosum Following Bilateral Deep Inferior Epigastric Perforator Flaps. J Reconstr Microsurg Open. 2016 Sep 28;01(02):125–7.

Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-Induced Pyoderma Gangrenosum: A Review. Vol. 19, American Journal of Clinical Dermatology. Springer International Publishing; 2018. p. 67–77.

Haag C, Hansen T, Hajar T, Latour E, Keller J, Shinkai K, et al. Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. Journal of Investigative Dermatology. 2021 Jan 1;141(1):59–63.

Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Vol. 14, Expert Review of Clinical Immunology. Taylor and Francis Ltd; 2018. p. 225–33.

Vigl K, Posch C, Richter L, Monshi B, Rappersberger K. Pyoderma gangrenosum during pregnancy – treatment options revisited. Journal of the European Academy of Dermatology and Venereology. 2016 Nov 1;30(11):1981–4.

George C, Deroide F, Rustin M. Pyoderma gangrenosum-a guide to diagnosis and management. Vol. 17, MEDICINE Clinical Medicine. 2017.

Shrestha S, Aryal A. Pyoderma Gangrenosum with Positive Antinuclear Antibody, in the Absence of Systemic Association. Nepal Journal of Dermatology, Venereology & Leprology. 2018 Mar 29;16(1):66–9.

Köken Avşar A, Karakaş A, Uslu S. Propylthiouracil induced p-ANCA pyoderma gangrenosum: Case report and review of literature. Maltepe Tıp Dergisi. 2020 Aug 31;12(2):59–62.

Weizman A v., Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: A descriptive cohort study. J Cutan Med Surg. 2015 Mar 1;19(2):125–31.

Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: A review for the gastroenterologist. Vol. 24, Inflammatory Bowel Diseases. Oxford University Press; 2018. p. 2510–7.

Garieri P, Marcasciano M, Greto Ciriaco A, Spagnuolo R. Pyoderma Gangrenosum and inflammatory bowel disease: a combined medical and surgical approach – case report and literature review. 2022.

Fletcher J, Alhusayen R, Alavi A. Recent advances in managing and understanding pyoderma gangrenosum. F1000Res. 2019;8.

Feldman SR, Lacy FA, Huang WW. The safety of treatments used in pyoderma gangrenosum. Vol. 17, Expert Opinion on Drug Safety. Taylor and Francis Ltd; 2018. p. 55–61.

Pichler M, Larcher L, Holzer M. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: case series of 15 patients. J Am Acad Dermatol. 2016 Apr 1;74(4):758–60.

Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Vol. 14, Expert Review of Clinical Immunology. Taylor and Francis Ltd; 2018. p. 225–33.

Downloads

Published

2023-10-12

How to Cite

1.
Budiyarto L, Mumtazah DA, Triatmoko SE. Propylthiouracil Induced p-ANCA+ Pyoderma Gangrenosum with Inflammatory Bowel Disease in Pregnancy. J Pak Assoc Dermatol [Internet]. 2023Oct.12 [cited 2024Oct.5];33(4):1694-700. Available from: https://jpad.com.pk/index.php/jpad/article/view/2362

Issue

Section

Case Reports